

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA - Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted in consultation that prostate cancer is more common in African-Caribbean men and men over 60 years of age, and that men from lower socioeconomic backgrounds are less likely to survive prostate cancer than those from more affluent backgrounds.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No evidence was received of differential access to therapy or prognosis in these groups.

It was agreed in the scoping workshop that, should the topic proceed through the appraisal process, access to the technology should not be defined by any of the protected characteristics outlined in the current equalities legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope were required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

No

Approved by Associate Director (name): Elisabeth George

Date: 19/07/11